| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of General Internal Medicine (Gerontology and Geriatrics) (Drs. ten Dam, Westendorp, de Craen, and Blauw), Radiology (Drs. van den Jeuvel and van Buchem), and Neurology (Dr. Bollen), Leiden University Medical Center, the Netherlands; and Robertson Centre for Biostatistics (Dr. Ford), North Glasgow University NHS Trust, UK.
Address correspondence and reprint requests to Dr ten Dam, Section of Gerontology and Geriatrics, Department of Internal Medicine, C2-R Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands; e-mail: V.H.ten_Dam{at}lumc.nl
The authors examined the effect of pravastatin 40 mg daily on the progression of ischemic brain lesions using repeated brain MRI. After a mean treatment period of 33 months, there was an increase in total ischemic lesion load of 1.1 cm3 (p < 0.001) in the 270 placebo-treated subjects and 1.1 cm3 (p < 0.001) in the 265 pravastatin-treated subjects. There was no difference between the two treatment groups (p = 0.73).
*See the Appendix for a list of Group members.
Drs. Blauw, van Buchem, Bollen, and Westendorp contributed to the design and execution of the study and interpretation of the data. Drs. ten Dam and van den Heuvel collected the MRI data and contributed to the interpretation of the data equally. Drs. Ford and de Craen were responsible for the statistical analyses and contributed to the interpretation of the data. All authors contributed to the writing of the manuscript.
Sponsored by an investigator-initiated grant from Bristol Myers-Squibb, Princeton, NJ. The sponsor had no role in the design, data collection, data analyses, or data interpretation of the study or the writing of the paper.
Dr. Ford has a consultancy arrangement. Drs. Blauw, van Buchem, Bollen, Ford, and Westendorp received research support and travel grants.
Received August 20, 2004. Accepted in final form February 4, 2005.
Related Article
Neurology 2005 64: 1672-1673.
This article has been cited by other articles:
|
|
 |
|
  L. C. Silbert, C. Nelson, D. B. Howieson, M. M. Moore, and J. A. Kaye Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline Neurology, July 8, 2008; 71(2): 108 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Bowler Modern concept of vascular cognitive impairment Br. Med. Bull., September 1, 2007; 83(1): 291 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schmidt, K. Petrovic, S. Ropele, C. Enzinger, and F. Fazekas Progression of Leukoaraiosis and Cognition Stroke, September 1, 2007; 38(9): 2619 - 2625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. H. ten Dam, D. M. J. van den Heuvel, A. J. M. de Craen, E. L. E. M. Bollen, H. M. Murray, R. G. J. Westendorp, G. J. Blauw, and M. A. van Buchem Decline in Total Cerebral Blood Flow Is Linked with Increase in Periventricular but Not Deep White Matter Hyperintensities Radiology, April 1, 2007; 243(1): 198 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kumar, S. Savitz, G. Schlaug, L. Caplan, and M. Selim Antiplatelets, ACE inhibitors, and statins combination reduces stroke severity and tissue at risk Neurology, April 25, 2006; 66(8): 1153 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.T. Longstreth Jr Brain Vascular Disease Overt and Covert Stroke, October 1, 2005; 36(10): 2062 - 2063. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
